Veranova’s Macfarlan Smith subsidiary announced that it had completed a $10 million mid-scale API manufacturing expansion in Edinburgh, UK.
This new facility can produce highly active APIs as well as intermediates. It will meet the growing demand of generic opioid analgesics as well as anti-addiction drugs.
The API manufacturing expansion is the first of two investments, with the second expansion already underway. These investments will be worth $17 million when they are completed.
David Payne
API manufacturing expansion will help meet growing demandDavid Payne, director for Veranova’s Scotland manufacturing operations, said in a press release that the API manufacturing expansion would “help us to meet the increasing demands from our customers” and increase the flexibility of its assets base.
Niek Stapel, CEO of Veranova, noted that the facility opening undersco…